|
|
Prepublished online as a Blood First Edition Paper on February 6, 2003; DOI 10.1182/blood-2002-10-3017.
 Previous Article | Table of Contents | Next Article 
Blood, 1 June 2003, Vol. 101, No. 11, pp. 4569-4575
NEOPLASIA
Clinical and biologic implications of recurrent genomic aberrations in myeloma
Rafael Fonseca,
Emily Blood,
Montserrat Rue,
David Harrington,
Martin M. Oken,
Robert A. Kyle,
Gordon W. Dewald,
Brian Van Ness,
Scott A. Van Wier,
Kimberly J. Henderson,
Richard J. Bailey, and
Philip R. Greipp
From the Mayo Clinic Division of Hematology, the Department of Laboratory Medicine and Pathology, Rochester, MN; Eastern Cooperative Oncology Group (ECOG) Statistical Center, the Dana-Farber Cancer Institute, Boston, MA; the Virginia Piper Cancer Institute, Minneapolis, MN; and the University of Minnesota, Minneapolis, MN.
Nonrandom recurrent chromosomal abnormalities are ubiquitous in multiple myeloma (MM) and include, among others, translocations of the immunoglobulin heavy chain locus (IgH). IgH translocations in MM result in the up-regulation of oncogenes, and include more commonly t(11;14)(q13;q32), t(4;14)(p16;q32), and t(14;16)(q32;q23). Based on the recurrent nature of these translocations and their finding since the early stages of the plasma cell (PC) disorders, we hypothesized that they would confer biologic and clinical variability. In addition, deletions of 13q14 and 17p13 have also been associated with a shortened survival. We used cytoplasmic Ig—enhanced interphase fluorescent in situ hybridization to detect deletions (13q14 and 17p13.1), and translocations involving IgH in 351 patients treated with conventional chemotherapy entered into the Eastern Cooperative Oncology Group clinical trial E9486/9487. Translocations were frequently unbalanced with loss of one of the derivative chromosomes. The presence of t(4; 14)(p16;q32) (n = 42; 26 vs 45 months, P < .001), t(14;16)(q32;q23) (n = 15; 16 vs 41 months, P = .003), – 17p13 (n = 37; 23 vs 44 months, P = .005), and – 13q14 (n = 176; 35 vs 51 months, P = .028) were associated with shorter survival. A stratification of patients into 3 distinct categories allowed for prognostication: poor prognosis group (t(4;14)(p16;q32), t(14; 16)(q32;q23), and – 17p13), intermediate prognosis (– 13q14), and good prognosis group (all others), with median survivals of 24.7, 42.3, and 50.5 months, respectively (P < .001). This molecular cytogenetic classification identifies patients into poor, intermediate, and good risk categories. More importantly it provides further compelling evidence that MM is composed of subgroups of patients categorized according to their underlying genomic aberrations.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
L. Chiecchio, G. P. Dagrada, R. K.M. Protheroe, D. M. Stockley, A. G. Smith, K. H. Orchard, N. C.P. Cross, C. J. Harrison, F. M. Ross, and on behalf of the UK Myeloma Forum
Loss of 1p and rearrangement of MYC are associated with progression of smouldering myeloma to myeloma: sequential analysis of a single case
Haematologica,
July 1, 2009;
94(7):
1024 - 1028.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Roccaro, A. Sacco, B. Thompson, X. Leleu, A. K. Azab, F. Azab, J. Runnels, X. Jia, H. T. Ngo, M. R. Melhem, et al.
MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma
Blood,
June 25, 2009;
113(26):
6669 - 6680.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. H. Bryce, R. P. Ketterling, M. A. Gertz, M. Lacy, R. A. Knudson, S. Zeldenrust, S. Kumar, S. Hayman, F. Buadi, R. A. Kyle, et al.
Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis
Haematologica,
March 1, 2009;
94(3):
380 - 386.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Bink, E. Haralambieva, M. Kremer, G. Ott, C. Beham-Schmid, L. de Leval, S. C. Peh, H. R. Laeng, U. Jutting, P. Hutzler, et al.
Primary extramedullary plasmacytoma: similarities with and differences from multiple myeloma revealed by interphase cytogenetics
Haematologica,
April 1, 2008;
93(4):
623 - 626.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. W. Jenner, P. E. Leone, B. A. Walker, F. M. Ross, D. C. Johnson, D. Gonzalez, L. Chiecchio, E. Dachs Cabanas, G. Paolo Dagrada, M. Nightingale, et al.
Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma
Blood,
November 1, 2007;
110(9):
3291 - 3300.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Brousseau, X. Leleu, J. Gerard, T. Gastinne, A. Godon, F. Genevieve, M. Dib, J.-L. Lai, T. Facon, M. Zandecki, et al.
Hyperdiploidy Is a Common Finding in Monoclonal Gammopathy of Undetermined Significance and Monosomy 13 Is Restricted to These Hyperdiploid Patients
Clin. Cancer Res.,
October 15, 2007;
13(20):
6026 - 6031.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Younes, X. Leleu, E. Hatjiharissi, A.-S. Moreau, T. Hideshima, P. Richardson, K. C. Anderson, and I. M. Ghobrial
Targeting the Phosphatidylinositol 3-Kinase Pathway in Multiple Myeloma
Clin. Cancer Res.,
July 1, 2007;
13(13):
3771 - 3775.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Tatetsu, S. Ueno, H. Hata, Y. Yamada, M. Takeya, H. Mitsuya, D. G. Tenen, and Y. Okuno
Down-regulation of PU.1 by Methylation of Distal Regulatory Elements and the Promoter Is Required for Myeloma Cell Growth
Cancer Res.,
June 1, 2007;
67(11):
5328 - 5336.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Fonseca
Multiple myeloma and FISH (but no CHIPS)
Blood,
April 15, 2007;
109(8):
3132 - 3133.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Mulligan, C. Mitsiades, B. Bryant, F. Zhan, W. J. Chng, S. Roels, E. Koenig, A. Fergus, Y. Huang, P. Richardson, et al.
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib
Blood,
April 15, 2007;
109(8):
3177 - 3188.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Avet-Loiseau, M. Attal, P. Moreau, C. Charbonnel, F. Garban, C. Hulin, S. Leyvraz, M. Michallet, I. Yakoub-Agha, L. Garderet, et al.
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome
Blood,
April 15, 2007;
109(8):
3489 - 3495.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. J. Chng, S. Kumar, S. VanWier, G. Ahmann, T. Price-Troska, K. Henderson, T.-H. Chung, S. Kim, G. Mulligan, B. Bryant, et al.
Molecular Dissection of Hyperdiploid Multiple Myeloma by Gene Expression Profiling
Cancer Res.,
April 1, 2007;
67(7):
2982 - 2989.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Fonseca and A. K. Stewart
Targeted therapeutics for multiple myeloma: The arrival of a risk-stratified approach
Mol. Cancer Ther.,
March 1, 2007;
6(3):
802 - 810.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Dispenzieri, S. V. Rajkumar, M. A. Gertz, M. Q. Lacy, R. A. Kyle, P. R. Greipp, T. E. Witzig, J. A. Lust, S. J. Russell, S. R. Hayman, et al.
Treatment of Newly Diagnosed Multiple Myeloma Based on Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART): Consensus Statement
Mayo Clin. Proc.,
March 1, 2007;
82(3):
323 - 341.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Fonseca
Strategies for Risk-Adapted Therapy in Myeloma
Hematology,
January 1, 2007;
2007(1):
304 - 310.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Zhan, Y. Huang, S. Colla, J. P. Stewart, I. Hanamura, S. Gupta, J. Epstein, S. Yaccoby, J. Sawyer, B. Burington, et al.
The molecular classification of multiple myeloma
Blood,
September 15, 2006;
108(6):
2020 - 2028.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R. Cook, M. Hartke, J. Pettay, and R. R. Tubbs
Fluorescence in Situ Hybridization Analysis of Immunoglobulin Heavy Chain Translocations in Plasma Cell Myeloma Using Intact Paraffin Sections and Simultaneous CD138 Immunofluorescence
J. Mol. Diagn.,
September 1, 2006;
8(4):
459 - 465.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Sonneveld
Gain of 1q21 in multiple myeloma: from bad to worse?
Blood,
September 1, 2006;
108(5):
1426 - 1427.
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Hanamura, J. P. Stewart, Y. Huang, F. Zhan, M. Santra, J. R. Sawyer, K. Hollmig, M. Zangarri, M. Pineda-Roman, F. van Rhee, et al.
Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation
Blood,
September 1, 2006;
108(5):
1724 - 1732.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Trudel, A. K. Stewart, E. Rom, E. Wei, Z. H. Li, S. Kotzer, I. Chumakov, Y. Singer, H. Chang, S.-B. Liang, et al.
The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells
Blood,
May 15, 2006;
107(10):
4039 - 4046.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. J. Chng, G. J. Ahmann, K. Henderson, R. Santana-Davila, P. R. Greipp, M. A. Gertz, M. Q. Lacy, A. Dispenzieri, S. Kumar, S. V. Rajkumar, et al.
Clinical implication of centrosome amplification in plasma cell neoplasm
Blood,
May 1, 2006;
107(9):
3669 - 3675.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Cavo, C. Terragna, M. Renzulli, E. Zamagni, P. Tosi, N. Testoni, C. Nicci, D. Cangini, P. Tacchetti, T. Grafone, et al.
Poor Outcome With Front-Line Autologous Transplantation in t(4;14) Multiple Myeloma: Low Complete Remission Rate and Short Duration of Remission
J. Clin. Oncol.,
January 20, 2006;
24(3):
e4 - e5.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Z. Orlowski
Initial Therapy of Multiple Myeloma Patients Who Are Not Candidates for Stem Cell Transplantation
Hematology,
January 1, 2006;
2006(1):
338 - 347.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. W. Dewald, T. Therneau, D. Larson, Y. K. Lee, S. Fink, S. Smoley, S. Paternoster, A. Adeyinka, R. Ketterling, D. L. Van Dyke, et al.
Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma
Blood,
November 15, 2005;
106(10):
3553 - 3558.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Chen, B. Issa, S. Huang, E. Aston, J. Xu, M. Yu, A. R. Brothman, and M. Glenn
A Practical Approach to the Detection of Prognostically Significant Genomic Aberrations in Multiple Myeloma
J. Mol. Diagn.,
November 1, 2005;
7(5):
560 - 565.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Agnelli, S. Bicciato, M. Mattioli, S. Fabris, D. Intini, D. Verdelli, L. Baldini, F. Morabito, V. Callea, L. Lombardi, et al.
Molecular Classification of Multiple Myeloma: A Distinct Transcriptional Profile Characterizes Patients Expressing CCND1 and Negative for 14q32 Translocations
J. Clin. Oncol.,
October 10, 2005;
23(29):
7296 - 7306.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Jaksic, S. Trudel, H. Chang, Y. Trieu, X. Qi, J. Mikhael, D. Reece, C. Chen, and A. K. Stewart
Clinical Outcomes in t(4;14) Multiple Myeloma: A Chemotherapy-Sensitive Disease Characterized by Rapid Relapse and Alkylating Agent Resistance
J. Clin. Oncol.,
October 1, 2005;
23(28):
7069 - 7073.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. V. Rajkumar and R. A. Kyle
Multiple Myeloma: Diagnosis and Treatment
Mayo Clin. Proc.,
October 1, 2005;
80(10):
1371 - 1382.
[Abstract]
[PDF]
|
|
|
|
|
|
|
P. L. Bergsagel and W. M. Kuehl
Molecular Pathogenesis and a Consequent Classification of Multiple Myeloma
J. Clin. Oncol.,
September 10, 2005;
23(26):
6333 - 6338.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. K. Stewart and R. Fonseca
Prognostic and Therapeutic Significance of Myeloma Genetics and Gene Expression Profiling
J. Clin. Oncol.,
September 10, 2005;
23(26):
6339 - 6344.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Chang, A. K. Stewart, X. Y. Qi, Z. H. Li, Q. L. Yi, and S. Trudel
Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma
Blood,
July 1, 2005;
106(1):
353 - 355.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. Keats, C. A. Maxwell, B. J. Taylor, M. J. Hendzel, M. Chesi, P. L. Bergsagel, L. M. Larratt, M. J. Mant, T. Reiman, A. R. Belch, et al.
Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients
Blood,
May 15, 2005;
105(10):
4060 - 4069.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Trudel, Z. H. Li, E. Wei, M. Wiesmann, H. Chang, C. Chen, D. Reece, C. Heise, and A. K. Stewart
CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma
Blood,
April 1, 2005;
105(7):
2941 - 2948.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. M. Kuehl and P. L. Bergsagel
Early Genetic Events Provide the Basis for a Clinical Classification of Multiple Myeloma
Hematology,
January 1, 2005;
2005(1):
346 - 352.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Chang, C. Qi, Q.-L. Yi, D. Reece, and A. K. Stewart
p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation
Blood,
January 1, 2005;
105(1):
358 - 360.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. C. Gutierrez, J. L. Garcia, J. M. Hernandez, E. Lumbreras, M. Castellanos, A. Rasillo, G. Mateo, J. M. Hernandez, S. Perez, A. Orfao, et al.
Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma
Blood,
November 1, 2004;
104(9):
2661 - 2666.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. Maxwell, E. Rasmussen, F. Zhan, J. J. Keats, S. Adamia, E. Strachan, M. Crainie, R. Walker, A. R. Belch, L. M. Pilarski, et al.
RHAMM expression and isoform balance predict aggressive disease and poor survival in multiple myeloma
Blood,
August 15, 2004;
104(4):
1151 - 1158.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Hideshima, P. L. Bergsagel, W. M. Kuehl, and K. C. Anderson
Advances in biology of multiple myeloma: clinical applications
Blood,
August 1, 2004;
104(3):
607 - 618.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Magrangeas, M.-L. Cormier, G. Descamps, N. Gouy, L. Lode, M.-P. Mellerin, J.-L. Harousseau, R. Bataille, S. Minvielle, and H. Avet-Loiseau
Light-chain only multiple myeloma is due to the absence of functional (productive) rearrangement of the IgH gene at the DNA level
Blood,
May 15, 2004;
103(10):
3869 - 3875.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Trudel, S. Ely, Y. Farooqi, M. Affer, D. F. Robbiani, M. Chesi, and P. L. Bergsagel
Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma
Blood,
May 1, 2004;
103(9):
3521 - 3528.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Meyer, L. C. Hofbauer, A. Neubauer, M. Schoppet, C. M. Lu, R. C. Walker, B. Barlogie, and J. Shaughnessy Jr.
DKK1 in Multiple Myeloma
N. Engl. J. Med.,
April 1, 2004;
350(14):
1464 - 1466.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Fonseca, B. Barlogie, R. Bataille, C. Bastard, P. L. Bergsagel, M. Chesi, F. E. Davies, J. Drach, P. R. Greipp, I. R. Kirsch, et al.
Genetics and Cytogenetics of Multiple Myeloma: A Workshop Report
Cancer Res.,
February 15, 2004;
64(4):
1546 - 1558.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Fonseca, C. S. Debes-Marun, E. B. Picken, G. W. Dewald, S. C. Bryant, J. M. Winkler, E. Blood, M. M. Oken, R. Santana-Davila, N. Gonzalez-Paz, et al.
The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma
Blood,
October 1, 2003;
102(7):
2562 - 2567.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Barille-Nion, B. Barlogie, R. Bataille, P. L. Bergsagel, J. Epstein, R. G. Fenton, J. Jacobson, W. M. Kuehl, J. Shaughnessy, and G. Tricot
Advances in Biology and Therapy of Multiple Myeloma
Hematology,
January 1, 2003;
2003(1):
248 - 278.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
